Monash University

Monash University, a non-profit international research institution based in Victoria, Australia, operates as a recipient of federal research contracts and grants across the Department of Defense, Health and Human Services, and civilian agencies, delivering biomedical science, advanced materials research, and defense-relevant computational technologies as a prime recipient (72% of recent awards) and as a sub-recipient on collaborative research initiatives (28%).

Monash's federal research footprint centers on biomedical and neuroscience investigations, advanced materials for defense applications, and artificial intelligence systems. Representative prime-contract work includes a $4.95 million cost-no-fee DARPA award (January 2022, completed February 2026) for the Computational Cultural Understanding program developing cross-cultural language analysis tools for Department of Defense operators, a $399,988 FDA definitive contract (September 2023, scheduled completion June 2027) for pharmacokinetic and pharmacodynamic modeling to optimize antibiotic selection and dosing for urinary tract infections, and a $303,941 NIDA purchase order (September 2022, completed April 2024) for breeding pairs and research common marmosets. In the grant space, Monash holds a $839,940 Defense Health Agency project grant (CFDA 12.420, effective July 2026 through June 2028) investigating multisensory stimulation and PIEZO1 as therapeutic strategies for amyotrophic lateral sclerosis, a $223,560 Air Force Defense Research Sciences Program award (CFDA 12.800, September 2025 through September 2028) for mechano-acoustically enhanced resin injection hybrid repair of composite structures, and a $249,809 Office of Naval Research basic research award (CFDA 12.300, July 2025 through September 2026) for neuro-symbolic artificial intelligence systems for maritime autonomy. The university also holds a DARPA cooperative agreement on hierarchical abstractions and reasoning for neuro-symbolic systems (HARNESS, June 2023 through June 2027) and a cooperative agreement with the Bureau of East Asian and Pacific Affairs (September 2022 through September 2025) for post-quantum cryptography training in Indo-Pacific partner countries.

Customer concentration is broad but anchors with the Department of the Air Force (27 awards), Defense Health Agency (19 awards), and NIH's National Institute of Allergy and Infectious Diseases (16 awards), accounting for 43% of award count. By potential value, DARPA leads at $5 million across four awards, though the overall portfolio reflects research-funding patterns where individual award values are modest relative to dollar-obligated activity (combined obligations of $135.2 million against combined potential value of $7.2 million, reflecting multi-year periods of performance across a large number of small research grants and contracts). Monash serves 42 distinct customer agencies across contract and grant portfolios.

Monash operates as a prime recipient on the majority of its work; SCI-reportable service-contract activity is minimal (zero invoiced revenue in FY2023–FY2024, with 3.4 FTEs delivered in FY2024), indicating that Monash's federal engagement is research-intensive rather than services-heavy and sits outside the SCI reporting regime for the most part. As a sub-recipient, Monash collaborates with Albert Einstein College of Medicine, The General Hospital Corporation, University of Southern California, University of Michigan, and Columbia University on epilepsy research, cardiovascular and aging studies, antibiotic development, and neuroimaging analysis. Recent sub-recipient work includes support for post-traumatic epileptogenesis biomarkers and translational epilepsy platforms under Albert Einstein awards, ASPREE longitudinal aging studies under Massachusetts General Hospital prime awards, and HIV prevention implementation research in Nigeria under Washington University and Columbia University primes. Monash also held a single sub-contract with Chemonics International (December 2023) for maternal and child health program desk review and in-country engagement in an unspecified geography.

The activity trajectory shows sustained engagement from 2022 onward (12 awards in 2022 to a peak of 25 in 2023, settling at 21–22 awards annually in 2024–2025), with 15 awards reaching ultimate completion in the next twenty-four months and combined potential value of $400 thousand exposed to recompete. Monash operates in the Colleges, Universities, and Professional Schools NAICS category (9 awards) alongside Software Publishers (4 awards), positioning itself as a research institution with emerging computational and data-science offerings. The university does not compete under SBA set-asides and operates on a full-and-open basis across its federal portfolio.